Allison Kurian
Overview
Explore the profile of Allison Kurian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mabey B, Hughes E, Kucera M, Simmons T, Hullinger B, Pederson H, et al.
Genet Med
. 2024 Jun;
26(7):101128.
PMID: 38829299
Purpose: We previously described a combined risk score (CRS) that integrates a multiple-ancestry polygenic risk score (MA-PRS) with the Tyrer-Cuzick (TC) model to assess breast cancer (BC) risk. Here, we...
2.
Wojcik K, Kamil D, Zhang J, Wilson O, Smith L, Butera G, et al.
J Cancer Surviv
. 2024 Mar;
PMID: 38538922
Purpose: We reviewed existing personalized, web-based, interactive decision-making tools available to guide breast cancer treatment and survivorship care decisions in clinical settings. Methods: The study was conducted using the Preferred...
3.
Hughes E, Wagner S, Pruss D, Bernhisel R, Probst B, Abkevich V, et al.
JCO Precis Oncol
. 2022 Nov;
6:e2200084.
PMID: 36331239
Purpose: Polygenic risk scores (PRSs) for breast cancer (BC) risk stratification have been developed primarily in women of European ancestry. Their application to women of non-European ancestry has lagged because...
4.
Liang S, Richardson M, Wong D, Chen T, Colocci N, Kapp D, et al.
Int J Gynaecol Obstet
. 2022 Aug;
159(3):996-997.
PMID: 35976039
No abstract available.
5.
Weldon C, Trosman J, Liang S, Douglas M, Scheuner M, Kurian A, et al.
J Genet Couns
. 2022 Jul;
31(6):1394-1403.
PMID: 35900261
Multi-cancer gene panels for hereditary cancer syndromes (hereditary cancer panels, HCPs) are widely available, and some laboratories have programs that limit patients' out-of-pocket (OOP) cost share. However, little is known...
6.
Chen H, Fan S, Stone J, Thompson D, Douglas J, Li S, et al.
Breast Cancer Res
. 2022 Apr;
24(1):27.
PMID: 35414113
Background: Mammographic density (MD) phenotypes, including percent density (PMD), area of dense tissue (DA), and area of non-dense tissue (NDA), are associated with breast cancer risk. Twin studies suggest that...
7.
Rodriguez G, Ferguson J, Kurian A, Bondy M, Patel M
Am J Clin Oncol
. 2021 Sep;
44(11):580-587.
PMID: 34519677
Objectives: The coronavirus disease 2019 (COVID-19) pandemic abruptly disrupted cancer care. The impact of these disruptions on patient experiences remain relatively understudied. The objective of this study was to assess...
8.
Oakley-Girvan I, Davis S, Kurian A, Rosas L, Daniels J, Palesh O, et al.
JMIR Form Res
. 2021 Aug;
5(8):e22608.
PMID: 34398787
Background: Approximately 6.1 million adults in the United States serve as care partners for cancer survivors. Studies have demonstrated that engaging cancer survivors and their care partners through technology-enabled structured...
9.
Lin G, Trosman J, Douglas M, Weldon C, Scheuner M, Kurian A, et al.
J Genet Couns
. 2021 Jul;
31(1):130-139.
PMID: 34231930
The landscape of payment for genetic testing has been changing, with an increase in the number of laboratories offering testing, larger panel offerings, and lower prices. To determine the influence...
10.
Jayasekera J, Sparano J, Gray R, Isaacs C, Kurian A, ONeill S, et al.
JNCI Cancer Spectr
. 2020 Apr;
3(4):pkz062.
PMID: 32337487
Purpose: The Trial Assigning Individualized Options for Treatment (TAILORx) found chemotherapy could be omitted in many women with hormone receptor-positive, -negative, node-negative breast cancer and 21-gene recurrence scores (RS) 11-25,...